BioCentury
ARTICLE | Clinical News

Mylotarg gemtuzumab ozogamicin regulatory update

June 28, 2010 7:00 AM UTC

Pfizer will withdraw Mylotarg gemtuzumab at the request of FDA after the cancer drug plus chemotherapy did not demonstrate improved survival and produced a significantly higher rate of fatal induction...